
New York—The $935 million acquisition of Eyetech Pharmaceuticals Inc. by OSI Pharmaceuticals Inc. will boost research and development (R&D) opportunities for both companies, while preserving Eyetech's integrity as a stand-alone business unit, according to leaders of both organizations.